Trial Profile

Protocol Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 24 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cagrilintide/semaglutide (Primary) ; Cagrilintide; Semaglutide
Indications Obesity
Focus Registrational; Therapeutic Use
Acronyms REDEFINE 1
Sponsors Novo Nordisk

Most Recent Events

10 Mar 2025 The detailed results from REDEFINE 1 and REDEFINE 2 will be presented at a scientific conference in 2025.
20 Dec 2024 Primary endpoint (CagriSema 2.4 mg/2.4 mg versus placebo: Achievement of greater than or equal to () 5% weight reduction) has been met ,according to a Novo Nordisk Media Release.
20 Dec 2024 Results presented in a Novo Nordisk Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com